Symbols / IVA
IVA Chart
About
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.41B |
| Enterprise Value | 954.81M | Income | -311.06M | Sales | 16.97M |
| Book/sh | -0.08 | Cash/sh | 0.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 84 | IPO | — |
| P/E | — | Forward P/E | -5.50 | PEG | — |
| P/S | 83.12 | P/B | -89.96 | P/C | — |
| EV/EBITDA | -9.97 | EV/Sales | 56.27 | Quick Ratio | 2.49 |
| Current Ratio | 2.96 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.43 | EPS next Y | -1.24 | EPS Growth | — |
| Revenue Growth | 105.20% | Earnings | 2026-03-30 | ROA | -56.77% |
| ROE | — | ROIC | — | Gross Margin | 95.19% |
| Oper. Margin | -9.92% | Profit Margin | 0.00% | Shs Outstand | 206.35M |
| Shs Float | 80.86M | Short Float | 0.36% | Short Ratio | 1.03 |
| Short Interest | — | 52W High | 7.98 | 52W Low | 2.67 |
| Beta | 0.89 | Avg Volume | 411.47K | Volume | 163.81K |
| Target Price | $15.48 | Recom | Strong_buy | Prev Close | $6.74 |
| Price | $6.79 | Change | 0.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.48
Mean price target
2. Current target
$6.79
Latest analyst target
3. DCF / Fair value
$-6.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.79
Low
$8.80
High
$26.00
Mean
$15.48
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | init | Barclays | — → Overweight | $18 |
| 2026-01-12 | init | Leerink Partners | — → Outperform | $12 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $11 |
| 2025-11-06 | init | Wolfe Research | — → Outperform | $13 |
| 2025-10-09 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-09-30 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2025-09-02 | main | Guggenheim | Buy → Buy | $13 |
| 2025-08-27 | init | Piper Sandler | — → Overweight | $26 |
| 2025-04-04 | main | Guggenheim | Buy → Buy | $9 |
| 2025-04-02 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-11-22 | main | Stifel | Buy → Buy | $17 |
| 2024-11-12 | init | UBS | — → Neutral | $3 |
| 2024-10-15 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-09-26 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-26 | main | Stifel | Buy → Buy | $20 |
| 2024-04-08 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
News
RSS: Latest IVA news- Inventiva S.A. (IVA) Stock Analysis: Biotech Breakthroughs With 131% Potential Upside - DirectorsTalk Interviews Sat, 21 Feb 2026 05
- Workiva (WK) Q4 2025 Earnings: Revenue Beats, Stock Gains - News and Statistics - IndexBox Fri, 20 Feb 2026 19
- Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know - Yahoo Finance hu, 08 Jan 2026 08
- Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research Fri, 26 Sep 2025 07
- Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire Wed, 04 Feb 2026 08
- New Analyst Forecast: $IVA Given 'Buy' Rating | IVA Stock News - Quiver Quantitative hu, 09 Oct 2025 07
- H.C. Wainwright reiterates Buy rating on Inventiva stock at $24 price target - Investing.com Wed, 28 Jan 2026 08
- Inventiva Posts Preliminary 2025 Results and Extends Cash Runway After Major U.S. Offering - TipRanks ue, 17 Feb 2026 11
- Wolfe Research Initiates Coverage on IVA with Outperform Rating - GuruFocus hu, 06 Nov 2025 08
- Inventiva S.A. (IVA) Stock Analysis: A Biotech with 279.78% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews Fri, 07 Nov 2025 08
- Are You Looking for a Top Momentum Pick? Why Inventiva S.A. Sponsored ADR (IVA) is a Great Choice - Yahoo Finance Mon, 26 Jan 2026 08
- Piper Sandler initiates Inventiva stock with Overweight rating on MASH potential - Investing.com Wed, 27 Aug 2025 07
- This is Why Wall Street is Bullish on Inventiva S.A. (IVA) - Yahoo Finance hu, 18 Dec 2025 08
- Inventiva S.A. (IVA) Stock Analysis: A Promising Biotech With 170% Upside Potential - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- Stifel reiterates Buy rating on Inventiva stock, cites lanifibranor’s unique profile - Investing.com hu, 09 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -19.63M | -226.25K | 1.76K | 526.02K |
| TaxRateForCalcs | 0.25 | 0.25 | 0.00 | 0.27 |
| NormalizedEBITDA | -88.00M | -101.14M | -54.82M | -50.95M |
| TotalUnusualItems | -78.53M | -905.00K | 2.93M | 1.99M |
| TotalUnusualItemsExcludingGoodwill | -78.53M | -905.00K | 2.93M | 1.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -184.21M | -110.43M | -54.27M | -49.63M |
| ReconciledDepreciation | 5.20M | 2.60M | 1.70M | -1.29M |
| EBITDA | -166.53M | -102.04M | -51.89M | -48.96M |
| EBIT | -171.72M | -104.64M | -53.59M | -49.14M |
| NetInterestIncome | -11.07M | -4.23M | -364.00K | -86.00K |
| InterestExpense | 12.18M | 5.18M | 707.00K | 138.00K |
| InterestIncome | 1.14M | 991.00K | 390.00K | 57.00K |
| NormalizedIncome | -125.31M | -109.75M | -57.20M | -51.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -184.21M | -110.43M | -54.27M | -49.63M |
| TotalExpenses | 103.19M | 120.14M | 69.04M | 55.37M |
| TotalOperatingIncomeAsReported | -97.56M | -102.71M | -57.11M | -52.11M |
| DilutedAverageShares | 59.78M | 45.35M | 41.45M | 39.17M |
| BasicAverageShares | 59.78M | 45.35M | 41.45M | 39.17M |
| DilutedEPS | -3.08 | -2.43 | -1.31 | -1.27 |
| BasicEPS | -3.08 | -2.43 | -1.31 | -1.27 |
| DilutedNIAvailtoComStockholders | -184.21M | -110.43M | -54.27M | -49.63M |
| NetIncomeCommonStockholders | -184.21M | -110.43M | -54.27M | -49.63M |
| NetIncome | -184.21M | -110.43M | -54.27M | -49.63M |
| NetIncomeIncludingNoncontrollingInterests | -184.21M | -110.42M | -54.27M | -49.64M |
| NetIncomeContinuousOperations | -184.21M | -110.42M | -54.27M | -49.64M |
| TaxProvision | 313.00K | 607.00K | -20.00K | 364.00K |
| PretaxIncome | -183.90M | -109.82M | -54.29M | -49.27M |
| OtherIncomeExpense | -78.84M | -2.92M | 2.93M | 1.99M |
| SpecialIncomeCharges | -3.73M | -44.00K | -130.00K | -943.00K |
| GainOnSaleOfPPE | -10.00K | 0.00 | -9.00K | 9.00K |
| WriteOff | 372.00K | 0.00 | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 1.79M | 0.00 | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 1.56M | 44.00K | 121.00K | 952.00K |
| EarningsFromEquityInterest | -313.00K | -2.02M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -74.80M | -861.00K | 3.06M | 2.93M |
| NetNonOperatingInterestIncomeExpense | -11.07M | -4.23M | -364.00K | -86.00K |
| TotalOtherFinanceCost | 34.00K | 46.00K | 47.00K | 5.00K |
| InterestExpenseNonOperating | 12.18M | 5.18M | 707.00K | 138.00K |
| InterestIncomeNonOperating | 1.14M | 991.00K | 390.00K | 57.00K |
| OperatingIncome | -93.99M | -102.67M | -56.86M | -51.17M |
| OperatingExpense | 103.19M | 120.14M | 69.04M | 55.37M |
| OtherOperatingExpenses | -5.49M | -5.69M | -6.93M | -6.50M |
| OtherTaxes | 0.00 | 0.00 | 2.22M | |
| ProvisionForDoubtfulAccounts | 0.00 | 0.00 | -333.00K | |
| DepreciationAmortizationDepletionIncomeStatement | 694.00K | 209.00K | 220.00K | 176.00K |
| DepreciationAndAmortizationInIncomeStatement | 694.00K | 209.00K | 220.00K | 176.00K |
| ResearchAndDevelopment | 90.88M | 110.01M | 60.47M | 48.45M |
| SellingGeneralAndAdministration | 17.10M | 15.61M | 15.28M | 11.34M |
| SellingAndMarketingExpense | 1.69M | 1.75M | 2.37M | 151.00K |
| GeneralAndAdministrativeExpense | 15.41M | 13.85M | 12.91M | 11.19M |
| OtherGandA | 9.37M | 8.88M | 8.73M | 7.42M |
| SalariesAndWages | 6.04M | 4.97M | 4.18M | 3.77M |
| TotalRevenue | 9.20M | 17.48M | 12.18M | 4.19M |
| OperatingRevenue | 9.20M | 17.48M | 12.18M | 4.19M |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 120.52K | 106.11K | ||
| OrdinarySharesNumber | 95.66M | 52.12M | 42.13M | 40.87M |
| ShareIssued | 95.78M | 52.22M | 42.13M | 40.87M |
| NetDebt | 4.01M | |||
| TotalDebt | 54.33M | 37.49M | 34.52M | 10.12M |
| TangibleBookValue | -106.69M | -32.57M | 44.91M | 88.10M |
| InvestedCapital | -56.97M | -1.11M | 75.48M | 98.86M |
| WorkingCapital | -9.22M | -1.97M | 75.68M | 92.72M |
| NetTangibleAssets | -106.69M | -32.57M | 44.91M | 88.10M |
| CapitalLeaseObligations | 4.66M | 6.57M | 4.51M | 130.00K |
| CommonStockEquity | -106.65M | -32.03M | 45.48M | 88.87M |
| TotalCapitalization | -60.32M | -4.12M | 70.91M | 97.61M |
| TotalEquityGrossMinorityInterest | -106.65M | -32.03M | 45.48M | 88.87M |
| StockholdersEquity | -106.65M | -32.03M | 45.48M | 88.87M |
| GainsLossesNotAffectingRetainedEarnings | -172.55M | -123.99M | -74.56M | -26.98M |
| OtherEquityAdjustments | -173.15M | -124.58M | -74.29M | -26.82M |
| ForeignCurrencyTranslationAdjustments | 600.00K | 596.00K | -271.00K | -164.00K |
| RetainedEarnings | -184.21M | -110.43M | -54.27M | -49.63M |
| AdditionalPaidInCapital | 249.16M | 201.86M | 173.89M | 165.07M |
| CapitalStock | 957.00K | 521.00K | 421.00K | 409.00K |
| CommonStock | 957.00K | 521.00K | 421.00K | 409.00K |
| TotalLiabilitiesNetMinorityInterest | 225.61M | 101.59M | 70.53M | 33.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 104.88M | 51.43M | 39.83M | 10.27M |
| OtherNonCurrentLiabilities | 30.24M | 7.36M | -2.00K | -2.00K |
| DerivativeProductLiabilities | 24.32M | 10.27M | 9.88M | 0.00 |
| EmployeeBenefits | 1.76M | 1.56M | 1.23M | 1.43M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.76M | 1.56M | 1.23M | 1.43M |
| NonCurrentDeferredLiabilities | 107.00K | 70.00K | 55.00K | 0.00 |
| NonCurrentDeferredRevenue | 107.00K | 70.00K | 55.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 48.46M | 32.18M | 28.66M | 8.84M |
| LongTermCapitalLeaseObligation | 2.13M | 4.27M | 3.23M | 92.00K |
| LongTermDebt | 46.33M | 27.91M | 25.43M | 8.75M |
| CurrentLiabilities | 120.73M | 50.16M | 30.70M | 22.85M |
| OtherCurrentLiabilities | 73.40M | -1.00K | 1.00K | |
| CurrentDeferredLiabilities | 0.00 | 6.00K | 6.00K | 180.00K |
| CurrentDeferredRevenue | 0.00 | 6.00K | 6.00K | 0.00 |
| CurrentDeferredTaxesLiabilities | 0.00 | 0.00 | 180.00K | |
| CurrentDebtAndCapitalLeaseObligation | 5.87M | 5.31M | 5.85M | 1.28M |
| CurrentCapitalLeaseObligation | 2.52M | 2.30M | 1.28M | 38.00K |
| CurrentDebt | 3.35M | 3.01M | 4.57M | 1.24M |
| OtherCurrentBorrowings | 3.35M | 3.01M | 4.57M | 1.24M |
| PayablesAndAccruedExpenses | 41.46M | 44.84M | 24.84M | 21.39M |
| CurrentAccruedExpenses | 1.74M | 1.54M | 1.34M | 1.23M |
| Payables | 39.72M | 43.30M | 23.50M | 20.16M |
| OtherPayable | 2.94M | 1.89M | 1.88M | 4.50M |
| TotalTaxPayable | 3.92M | 3.73M | 2.27M | 1.06M |
| AccountsPayable | 32.86M | 37.68M | 19.36M | 14.60M |
| TotalAssets | 118.97M | 69.56M | 116.00M | 121.98M |
| TotalNonCurrentAssets | 7.46M | 21.37M | 9.62M | 6.41M |
| OtherNonCurrentAssets | -2.00K | |||
| NonCurrentPrepaidAssets | 1.05M | 10.05M | 1.60M | 2.44M |
| NonCurrentDeferredAssets | 217.00K | 225.00K | 0.00 | 0.00 |
| NonCurrentDeferredTaxesAssets | 217.00K | 225.00K | 0.00 | 0.00 |
| NonCurrentAccountsReceivable | 65.00K | |||
| InvestmentsAndAdvances | 1.14M | 1.43M | 0.00 | 0.00 |
| InvestmentinFinancialAssets | 9.00M | 700.00K | 1.75M | |
| AvailableForSaleSecurities | 9.00M | 700.00K | 1.75M | |
| LongTermEquityInvestment | 1.14M | 1.43M | 0.00 | 0.00 |
| GoodwillAndOtherIntangibleAssets | 48.00K | 542.00K | 568.00K | 770.00K |
| OtherIntangibleAssets | 48.00K | 542.00K | 568.00K | 770.00K |
| NetPPE | 5.00M | 9.13M | 7.39M | 3.20M |
| AccumulatedDepreciation | -15.19M | -10.71M | -8.56M | -7.12M |
| GrossPPE | 20.20M | 19.84M | 15.94M | 10.32M |
| ConstructionInProgress | 20.00K | 115.00K | 65.00K | 59.00K |
| OtherProperties | 10.72M | 10.48M | 6.78M | 1.56M |
| MachineryFurnitureEquipment | 5.82M | 5.60M | 5.46M | 5.12M |
| BuildingsAndImprovements | 3.47M | 3.47M | 3.47M | 3.41M |
| LandAndImprovements | 172.00K | 172.00K | 172.00K | 172.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 111.51M | 48.19M | 106.38M | 115.58M |
| OtherCurrentAssets | 349.00K | 422.00K | 282.00K | 763.00K |
| HedgingAssetsCurrent | 0.00 | 0.00 | ||
| PrepaidAssets | 2.44M | 4.66M | 8.60M | 7.45M |
| Inventory | 0.00 | 417.00K | 373.00K | 392.00K |
| OtherInventories | 417.00K | 373.00K | 392.00K | |
| Receivables | 12.16M | 15.71M | 9.34M | 11.59M |
| OtherReceivables | 1.63M | 1.48M | 279.00K | 386.00K |
| TaxesReceivable | 10.00M | 10.42M | 9.06M | 7.20M |
| AccountsReceivable | 531.00K | 3.81M | 0.00 | 4.00M |
| CashCashEquivalentsAndShortTermInvestments | 96.56M | 26.99M | 87.78M | 95.38M |
| OtherShortTermInvestments | 0.00 | 70.00K | 1.05M | 8.83M |
| CashAndCashEquivalents | 96.56M | 26.92M | 86.74M | 86.55M |
| CashEquivalents | 70.66M | 17.93M | 16.80M | 42.90M |
| CashFinancial | 25.91M | 8.98M | 69.94M | 43.65M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -86.26M | -82.15M | -45.49M | -48.16M |
| RepaymentOfDebt | -4.99M | -4.10M | -1.77M | -28.00K |
| IssuanceOfDebt | 24.92M | 0.00 | 30.21M | 0.00 |
| IssuanceOfCapitalStock | 57.34M | 30.59M | 8.83M | 25.48M |
| CapitalExpenditure | -333.00K | -540.00K | -561.00K | -534.00K |
| EndCashPosition | 96.56M | 26.92M | 86.74M | 86.55M |
| BeginningCashPosition | 26.92M | 86.74M | 86.55M | 105.69M |
| EffectOfExchangeRateChanges | 1.24M | 445.00K | -1.02M | 4.84M |
| ChangesInCash | 68.41M | -60.26M | 1.21M | -23.98M |
| FinancingCashFlow | 145.59M | 29.08M | 37.27M | 25.45M |
| CashFlowFromContinuingFinancingActivities | 145.59M | 29.08M | 37.27M | 25.45M |
| NetOtherFinancingCharges | 10.10M | 2.59M | 30.21M | |
| ProceedsFromStockOptionExercised | 58.23M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 57.34M | 30.59M | 8.83M | 25.48M |
| CommonStockIssuance | 57.34M | 30.59M | 8.83M | 25.48M |
| NetIssuancePaymentsOfDebt | 19.92M | -4.10M | 28.44M | -28.00K |
| NetLongTermDebtIssuance | 19.92M | -4.10M | 28.44M | -28.00K |
| LongTermDebtPayments | -4.99M | -4.10M | -1.77M | -28.00K |
| LongTermDebtIssuance | 24.92M | 0.00 | 30.21M | 0.00 |
| InvestingCashFlow | 8.74M | -7.73M | 8.87M | -1.79M |
| CashFlowFromContinuingInvestingActivities | 8.74M | -7.73M | 8.87M | -1.79M |
| NetOtherInvestingChanges | 1.00K | 1.00K | ||
| NetInvestmentPurchaseAndSale | 9.08M | -7.32M | 9.39M | -1.35M |
| SaleOfInvestment | 9.08M | 978.00K | 9.39M | |
| PurchaseOfInvestment | -8.30M | -1.00K | -1.35M | |
| NetPPEPurchaseAndSale | -333.00K | -409.00K | -520.00K | -445.00K |
| SaleOfPPE | 0.00 | 131.00K | 41.00K | 89.00K |
| PurchaseOfPPE | -333.00K | -540.00K | -561.00K | -534.00K |
| OperatingCashFlow | -85.93M | -81.61M | -44.93M | -47.63M |
| CashFlowFromContinuingOperatingActivities | -85.93M | -81.61M | -44.93M | -47.63M |
| TaxesRefundPaid | 5.33M | 5.22M | 3.55M | 7.96M |
| ChangeInWorkingCapital | 1.68M | 17.31M | 5.71M | 979.00K |
| ChangeInOtherWorkingCapital | 1.79M | 3.19M | -1.69M | -1.23M |
| ChangeInPayablesAndAccruedExpense | -3.34M | 20.00M | 3.54M | 7.60M |
| ChangeInPayable | -3.34M | 20.00M | 3.54M | 7.60M |
| ChangeInInventory | 417.00K | -44.00K | 19.00K | -72.00K |
| ChangeInReceivables | 2.81M | -5.84M | 3.84M | -5.32M |
| OtherNonCashItems | 87.81M | 2.15M | 1.08M | 737.00K |
| StockBasedCompensation | 3.58M | 3.97M | 2.22M | 2.09M |
| DeferredTax | -4.80M | -4.74M | -5.26M | -3.27M |
| DeferredIncomeTax | -4.80M | -4.74M | -5.26M | -3.27M |
| DepreciationAmortizationDepletion | 5.20M | 2.60M | 1.70M | -1.29M |
| DepreciationAndAmortization | 5.20M | 2.60M | 1.70M | -1.29M |
| Depreciation | 5.20M | 2.60M | 1.70M | -1.29M |
| OperatingGainsLosses | -518.00K | 2.31M | 343.00K | -5.20M |
| EarningsLossesFromEquityInvestments | 152.00K | 2.02M | 0.00 | 0.00 |
| NetForeignCurrencyExchangeGainLoss | -1.13M | 297.00K | 343.00K | -5.20M |
| GainLossOnSaleOfPPE | 456.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -184.21M | -110.43M | -54.27M | -49.63M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IVA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|